发明授权
US09140703B2 Combined F2-isoprostane and myeloperoxidase detection, a risk indicator for cardiovascular disease
有权
联合F2-异前列烷和髓过氧化物酶检测,心血管疾病的风险指标
- 专利标题: Combined F2-isoprostane and myeloperoxidase detection, a risk indicator for cardiovascular disease
- 专利标题(中): 联合F2-异前列烷和髓过氧化物酶检测,心血管疾病的风险指标
-
申请号: US12911425申请日: 2010-10-25
-
公开(公告)号: US09140703B2公开(公告)日: 2015-09-22
- 发明人: Stanley L. Hazen , Renliang Zhang
- 申请人: Stanley L. Hazen , Renliang Zhang
- 申请人地址: US OH Cleveland
- 专利权人: The Cleveland Clinic Foundation
- 当前专利权人: The Cleveland Clinic Foundation
- 当前专利权人地址: US OH Cleveland
- 代理机构: Tarolli, Sundheim, Covell & Tummino LLP
- 主分类号: C12Q1/28
- IPC分类号: C12Q1/28 ; C12Q1/26 ; G01N33/53 ; G01N33/573 ; C12N1/28
摘要:
Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from healthy controls. Such comparison characterizes the test subject's risk of developing CVD.
公开/授权文献
信息查询